Literature DB >> 15789122

Cellular processing of platinum anticancer drugs.

Dong Wang1, Stephen J Lippard.   

Abstract

Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy. Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs. This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signalling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death. Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15789122     DOI: 10.1038/nrd1691

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  847 in total

Review 1.  Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Ralf Baron; Klaus Scholich; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

2.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

3.  Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

Authors:  Alma Zecevic; Deepa Sampath; Brett Ewald; Rong Chen; William Wierda; William Plunkett
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

4.  Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Authors:  Johnny Moretto; Bruno Chauffert; François Ghiringhelli; Janice R Aldrich-Wright; Florence Bouyer
Journal:  Invest New Drugs       Date:  2010-06-10       Impact factor: 3.850

5.  Site-specific platinum(II) cross-linking in a ribozyme active site.

Authors:  Erich G Chapman; Victoria J DeRose
Journal:  J Am Chem Soc       Date:  2011-12-14       Impact factor: 15.419

6.  Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery.

Authors:  Adem Guven; Irene A Rusakova; Michael T Lewis; Lon J Wilson
Journal:  Biomaterials       Date:  2011-11-12       Impact factor: 12.479

7.  The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies cisplatin.

Authors:  Nataliya V Dolgova; Doug Olson; Svetlana Lutsenko; Oleg Y Dmitriev
Journal:  Biochem J       Date:  2009-04-01       Impact factor: 3.857

8.  Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.

Authors:  Courtney M Vaughn; Christopher P Selby; Yanyan Yang; David S Hsu; Aziz Sancar
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

9.  Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma.

Authors:  Hirotaka Konishi; Hitoshi Fujiwara; Hiroshi Itoh; Atsushi Shiozaki; Tomohiro Arita; Toshiyuki Kosuga; Ryo Morimura; Shuhei Komatsu; Daisuke Ichikawa; Kazuma Okamoto; Eigo Otsuji
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

10.  Kinetics and mechanism of the substitution reactions of [PtCl(bpma)]+, [PtCl(gly-met-S,N,N)] and their aqua analogues with L-methionine, glutathione and 5'-GMP.

Authors:  Zivadin D Bugarcić; Jovana Rosić; Biljana Petrović; Nadine Summa; Raph Puchta; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-08-21       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.